Pharma HCP Marketing: How to Build a Smarter Targeting Strategy in 2026

Pharma HCP marketing helps pharmaceutical companies educate and engage healthcare professionals (HCPs) who prescribe, recommend, dispense, or influence access to medicines. In the US, an effective strategy needs more than a list of doctors. It combines relevant audience selection, account-level understanding, coordinated channels, compliant content, and reliable data.

That matters because the route to a prescriber is changing. Many physicians now work within hospitals or corporate-owned groups, and access policies can limit sales-rep visits. Marketing teams need to understand both the individual HCP and the healthcare organization around them.

This guide explains how to build a pharma HCP marketing strategy, choose channels, manage key compliance considerations, and use healthcare data to make targeting more practical.

Key takeaways

• Start with the right audience. Define HCP segments by therapeutic area, specialty, relevant clinical activity, geography, and prescribing needs – not specialty alone.
• Map accounts as well as individuals. Employment and health-system affiliations can affect how medicines are evaluated and adopted.
• Coordinate channels around access and preference. Field engagement, email, virtual detailing, medical media, and peer programs each serve different purposes.
• Build compliance into planning. Promotional claims, HCP interactions, commercial email, and transfers of value may be subject to different rules.
• Keep contact data current. Practice changes and outdated contact details can undermine targeting and campaign delivery.

What is pharma HCP marketing?

Pharma HCP marketing is the communication and promotion of pharmaceutical products to healthcare professionals. Depending on the campaign, the audience may include physicians (MDs and DOs), nurse practitioners, physician assistants, pharmacists, and other professionals involved in treatment decisions.

For some products, the audience also extends to people who influence access at the organization level, such as pharmacy directors, formulary stakeholders, and members of pharmacy and therapeutics (P&T) committees. These groups do not all play the same role, so they should not be treated as one audience.

Pharma HCP marketing differs from direct-to-consumer marketing in several important ways:

• The content must be evidence-led. HCPs expect clinically relevant information that is accurate and appropriately supported.
• Product claims must be carefully controlled. Promotional materials need to follow applicable FDA requirements and align with approved labeling.
• The audience is specialized. A campaign for one therapeutic area may need a small, well-defined group rather than a broad list of healthcare professionals.

The practical lesson is simple: define who needs the information and why before deciding what to say or which channel to use.

Why pharma HCP marketing is changing in 2026

Three trends are especially relevant to US pharma teams: changes in physician employment, restricted access to some prescribers, and greater visibility into payments and transfers of value.

1. Physician employment changes the account map

The AMA’s Physician Practice Benchmark Survey found that 42.2% of physicians were in private practice in 2024, compared with 60.1% in 2012. A separate report from the Physicians Advocacy Institute and Avalere Health estimated that 82.0% of physicians were employed by hospitals or corporate entities as of January 1, 2026. These figures use different measures, so they should be understood in the context of their respective reports.

For pharma marketers, the implication is not that every treatment decision is made centrally. It is that a physician’s employer and care setting can influence access, purchasing processes, and formulary decisions. The relevant stakeholders vary by organization and product.

What to do: Add employer and organization affiliation to your target-account view. For priority accounts, confirm which stakeholders influence product evaluation and access instead of assuming the same structure applies everywhere. Ampliz’s list of IDNs in the US can support initial account research.

2. Rep access can be limited in priority specialties

Access varies by specialty, institution, geography, and individual policy. ZS’s 2025 oncology analysis reported that 68% of US oncologists were access restricted under its definition – seeing 70% or fewer of the representatives who called on them. The same analysis reported a 61% figure for hematology.

These figures do not mean that every oncologist refuses all representative visits. They do show why a field-only plan may not reach the full target audience.

What to do: Identify access constraints before assigning channels. For restricted audiences, consider compliant non-personal options such as email, virtual engagement, medical-journal media, and relevant educational programs. Use channel performance and HCP preferences to refine the mix over time.

3. Transfers of value are publicly reported

The federal Open Payments program makes certain payments and transfers of value from applicable manufacturers to covered recipients publicly available. CMS reported 16.16 million records totaling $13.18 billion for Program Year 2024.

Transparency reporting is one part of the wider compliance environment. It does not mean every interaction is prohibited, but it does make accurate documentation, appropriate review, and clear processes important.

How to build a pharma HCP marketing strategy

A useful strategy connects audience definition, account mapping, channel selection, content review, and measurement. Use the following workflow for a product launch or an in-market brand.

Step 1: Define the audience around the clinical use case

Start with the product’s approved indication, target therapeutic area, and the types of HCPs relevant to treatment. Then refine the audience using appropriate factors such as specialty, sub-specialty, geography, practice setting, and relevant clinical activity.

Depending on the use case and available data, procedure codes, claims, and prescribing data may help refine a segment. Confirm that the data is suitable for the intended use and interpret it within its limitations.

Example: For a therapy used in a specific inflammatory condition, a team might begin with relevant specialties, then narrow by geography and care setting. Additional clinical or claims-based criteria should be used only when they are appropriate for the product and the campaign objective.

Step 2: Map the organization around priority HCPs

For each priority HCP, capture relevant practice and employer information. Where account-level decisions matter, identify the parent health system, hospital or IDN affiliation, and the stakeholders involved in evaluation or formulary processes.

Do not assume every hospital uses the same decision process. Validate the account structure for high-priority organizations and keep the individual prescriber and account-level stakeholders distinct in your plan.

Step 3: Segment by potential, access, and campaign objective

A useful segment is more than a specialty label. Consider the campaign objective, relevance to the product, account priority, access constraints, and the role of the person you are trying to reach.

Avoid treating data-based estimates as a guarantee of prescribing behavior. Use available evidence to prioritize outreach, then assess results and refine segments with your commercial, medical, and analytics teams.

Step 4: Assign channels to each segment

Choose channels based on audience needs, access, content type, and operational capacity. A coordinated plan should give field and non-personal teams a shared view of target accounts and relevant interaction history, subject to your organization’s privacy and access controls.

Step 5: Plan content review before campaign launch

Build medical, legal, and regulatory (MLR) review into the timeline. Review promotional claims, supporting evidence, fair balance, intended audience, and channel-specific requirements before materials are deployed. Do not assume a claim approved for one format can automatically be reused in another.

Step 6: Refresh contact and affiliation data

HCPs change practices, employers, and contact details. Set a refresh schedule that fits the campaign cycle, and check priority records before a major outreach wave. Monitor invalid email addresses, disconnected phone numbers, and affiliation changes so the team can correct records rather than repeatedly using outdated information.

Ampliz states that it re-verifies contact details on a 30-day cycle. Treat verification as an important data-quality process, not a guarantee that every field is always correct or that a campaign will be compliant.

Step 7: Measure performance by segment and objective

Measure more than total sends or rep calls. Depending on the program, useful measures can include:

• Percentage of the defined target audience reached
• Email delivery, bounce, opt-out, and engagement rates
• Virtual meeting requests and completed engagements
• Field activity against priority accounts
• Engagement by specialty, access tier, and account
• Downstream outcomes available through your approved analytics and measurement systems

Interpret results carefully. Engagement does not automatically demonstrate a change in prescribing, and prescribing outcomes may be affected by factors beyond marketing activity.

Which channels should pharma HCP marketers use?

Omnichannel HCP marketing coordinates relevant touchpoints around the HCP and campaign objective. It does not mean sending the same message everywhere or maximizing the number of contacts. The aim is to provide appropriate, consistent information through channels that fit the audience and the applicable rules.

There is no universal channel mix for every brand or specialty. Test a sensible mix, monitor outcomes by segment, and adjust based on evidence rather than assuming one channel always performs best.

For more on the email component, see Ampliz’s guide to email marketing for pharmaceuticals.

Compliance considerations for US pharma HCP marketing

This section is a practical overview, not legal advice. Requirements depend on the product, audience, material, activity, and jurisdiction. Your legal, medical, regulatory, privacy, and compliance teams should determine which rules apply to each campaign.

• FDA promotional requirements: Prescription-drug promotion must comply with applicable FDA requirements, including rules concerning truthful, non-misleading, and appropriately balanced communications. Review claims against approved labeling and the context in which they will appear. See the FDA’s guidance on truthful prescription drug advertising and promotion.
• PhRMA Code: The PhRMA Code provides industry standards for interactions with healthcare professionals. Check the current Code and your organization’s policies when planning meals, speaker programs, consulting arrangements, or other interactions.
• CMS Open Payments: Certain payments and transfers of value must be reported under applicable federal requirements. Confirm reporting responsibilities and documentation with your compliance team.
• Commercial email: CAN-SPAM requirements can apply to commercial email. Ensure that sending practices, sender identification, opt-out processes, and suppression lists are handled appropriately.
• Privacy and data use: HIPAA concerns protected health information and does not automatically apply to every professional contact record. Confirm the lawful basis, permitted use, contractual terms, and privacy obligations for the data and campaign in question.

Ampliz describes its platform as working with provider directory data rather than storing patient PHI, and its materials reference HIPAA-related safeguards, GDPR and CCPA processes, and a business associate agreement available on request. For current details, review the Ampliz compliance information and obtain the documentation needed for your organization’s vendor review.

Using a contact database does not by itself make a marketing campaign compliant. The campaign owner remains responsible for appropriate audience selection, content approval, channel practices, and required documentation.

How Ampliz can support pharma HCP targeting

Ampliz is a healthcare B2B data platform that helps commercial teams find and work with healthcare contacts and organizations. For pharma marketers, it can support the data and account-research steps of a targeting workflow. It should sit alongside – not replace – your medical, legal, regulatory, CRM, analytics, and campaign systems.

Depending on the product access and data fields available to your team, Ampliz capabilities include:

• HCP Lookup: Search healthcare professionals using fields such as specialty, sub-specialty, geography, NPI, procedure codes, and available claims or prescribing attributes.
• Executive Search: Research relevant healthcare organization leaders and decision-makers. Confirm specific role coverage for the accounts and stakeholders you need.
• Hospital Analytics: Explore hospital and health-system relationships, including relevant IDN and GPO affiliations where available.
• Contact verification: Ampliz says it re-verifies email, phone, and NPI-related records every 30 days. Teams should still validate priority records and monitor campaign-level delivery outcomes.
• NPI Lookup and data enrichment: Enrich or investigate records when you have an NPI or an existing list that needs additional professional contact or organization information.

Explore the Ampliz healthcare data platform to understand the available workflows and data fields. Before relying on any specific filter or stakeholder category, confirm its current availability with your Ampliz contact.

Want to review your HCP targeting workflow? Book a demo with Ampliz to discuss how healthcare contact data, verification, and organization mapping could support your team’s process.

A practical checklist for your next HCP campaign

Before launch, confirm that your team has:

1. Defined the target audience around the product and campaign objective.
2. Segmented HCPs using relevant, supportable criteria.
3. Mapped priority practices and health-system affiliations where they matter.
4. Selected channels based on access, audience needs, and the content being delivered.
5. Completed the required medical, legal, regulatory, privacy, and compliance reviews.
6. Checked priority contact records and prepared a data-refresh schedule.
7. Set baseline metrics and defined how the campaign will be evaluated.

Frequently asked questions

What does HCP mean in pharma marketing?

HCP stands for healthcare professional. Depending on the campaign, it can include physicians, nurse practitioners, physician assistants, pharmacists, and other professionals involved in treatment or medicine-related decisions. Account-level stakeholders may also be relevant, but their roles should be distinguished from those of prescribers.

How can pharma companies reach HCPs who do not see sales representatives?

First, confirm the access restrictions and the HCP’s communication preferences. Depending on the audience and campaign, options may include approved email, virtual engagement, specialty media, and relevant educational programs. Keep content reviewed, follow applicable contact and opt-out requirements, and measure performance by segment.

Is pharma HCP marketing regulated in the US?

Yes. Applicable requirements can include FDA rules for prescription-drug promotion, CMS Open Payments reporting, commercial-email laws, privacy obligations, and industry codes such as the PhRMA Code. The exact requirements depend on the activity and should be confirmed by the organization’s legal and compliance teams.

What data is useful for HCP targeting?

Useful fields may include NPI, specialty and sub-specialty, practice location, employer or health-system affiliation, and professional contact details. Depending on the therapeutic area and intended use, additional attributes such as procedure codes, claims, or prescribing data may help refine segments. Validate data coverage, freshness, and permitted use before activation.

How often should HCP contact data be updated?

Refresh data before major campaign waves and set a regular cadence for active audiences. The appropriate schedule depends on campaign frequency, the reliability of the source, and the cost of using an outdated record. Ampliz says it re-verifies certain contact and identity fields every 30 days; teams should still monitor delivery and verify high-priority records.

Subbu

V. SubramanyamHead of Product at Ampliz | Healthcare Data & GTM Intelligence Expert
V. Subramanyam is the Head of Product at Ampliz, where he leads the strategy and development of healthcare data intelligence solutions that help sales, marketing, recruiting, and commercial teams identify and engage healthcare decision-makers across the United States.
With extensive experience in product management, healthcare data, B2B SaaS, GTM strategy, and sales intelligence, he focuses on building products that simplify healthcare prospecting through accurate physician, hospital, executive, and healthcare organization data. His work emphasizes data quality, enrichment, and AI-powered workflows that enable organizations to make faster, data-driven decisions.
Connect with Him:

LinkedIn: https://www.linkedin.com/in/vsubramanyam
Company: https://www.ampliz.com